Oncology Venture gets option to in-license European rights to IXEMPRA
By Nikita Chaurasia  Date: 2019-04-05

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Microsoft makes ‘carbon negative’ pledge to reach near zero emissions
Microsoft makes ‘carbon negative’ pledge to reach near zero emissions
By Nikita Chaurasia

Microsoft, a tech giant based in Redmond, Washington, has reportedly announced plans to go “carbon negative” by reducing carbon footprint from the atmosphere, by 2030. The technological company is placing strong emphasis on removing more...

Nissan, Renault denounce split rumors following Chairman Ghosn’s exit
Nissan, Renault denounce split rumors following Chairman Ghosn’s exit
By Nikita Chaurasia

The automakers ensure that the alliance was not under the danger of being dissolved. Renault shares have hit six years low after the split report. Automotive giants Nissan and Renault have recently denied reports of a possible split that resulte...

Visa to take over fintech firm ‘Plaid’ in $5.3 Bn acquisition deal
Visa to take over fintech firm ‘Plaid’ in $5.3 Bn acquisition deal
By Nikita Chaurasia

Visa, a financial services corporation, is reportedly acquiring Plaid, a start-up company based in San Francisco, in a deal worth $5.3 Bn. It is a long-term play that would position Visa as a leading company in the next decade and help Plaid scale it...

Dupont to invest $28Mn to produce advanced chip materials in S.Korea
Dupont to invest $28Mn to produce advanced chip materials in S.Korea
By Nikita Chaurasia

The company plans to develop a new facility in South Korea that would help reduce its dependency on Japan for semiconductor products. As Japan’s diplomatic relations with South Korea sour up, U.S. chemical company DuPont has revealed plans to...

Spotify unveils new streaming ad insertion tech to monetize podcasts
Spotify unveils new streaming ad insertion tech to monetize podcasts
By Nikita Chaurasia

Spotify Technology S.A., a Sweden based international media services provider, has reportedly announced a new podcast advertising technology called SAI (Streaming Ad Insertion) at the Consumer Electronics Show in Las Vegas. This new technology, for ...